Wuhan Mindray Bio-Medical Technology Co., Ltd.
Announcement No.: 2026-056
Announcement on the Self-Inspection Report of Relevant Parties in the Transaction Regarding Stock Trading
The Company and the entire Board of Directors guarantee that the content of this information disclosure is true, accurate, and complete, and contains no false records, misleading statements, or major omissions.
Wuhan Mindray Bio-Medical Technology Co., Ltd. (hereinafter referred to as the "Company") intends to acquire 100% equity of Wuhan Bikai'er Rescue Supplies Co., Ltd. held by Blue Sail Medical Co., Ltd. (hereinafter referred to as the "Transaction") by paying cash.
In accordance with the "Administrative Measures for Major Asset Reorganizations of Listed Companies" (hereinafter referred to as the "Reorganization Measures"), the "Format Rules for Information Disclosure of Publicly Issued Securities Companies No. 26 - Major Asset Reorganizations of Listed Companies" (hereinafter referred to as the "Format Rules No. 26"), the "Guiding Opinions on the Application of Regulatory Rules - Listed Companies No. 1" (hereinafter referred to as the "Listed Companies No. 1"), and the "Shenzhen Stock Exchange Listed Company Self-Regulatory Supervision Guidelines No. 8 - Major Asset Reorganizations" (hereinafter referred to as the "Self-Regulatory Supervision Guidelines No. 8"), etc., the Company has conducted insider information registration and self-inspection for parties related to this transaction and their personnel, as follows:
I. Inspection Period for Stock Trading by Relevant Parties in the Transaction
In accordance with the relevant provisions of the "Reorganization Measures," "Format Rules No. 26," "Listed Companies No. 1," and "Self-Regulatory Supervision Guidelines No. 8," etc., the self-inspection period for trading of listed company stocks in this transaction is from 6 months prior to the Company's first disclosure of the restructuring matter to the disclosure of the restructuring report, i.e., from June 30, 2025, to June 29, 2026 (hereinafter referred to as the "Self-Inspection Period" or "Inspection Period").
II. Scope of Inspection for Relevant Parties in the Transaction
The scope of inspection for relevant parties in this transaction includes:
-
The Company and its directors, senior management personnel, and relevant informed personnel;
-
The counterparty to the transaction and its directors, senior management personnel, and relevant informed personnel;
-
The Company's controlling shareholder and its directors, senior management personnel, and relevant informed personnel;
-
The target company and its directors, supervisors, senior management personnel, and relevant informed personnel;
-
Intermediary agencies providing services for this transaction and their personnel;
-
Other legal persons and natural persons who are aware of the insider information of this transaction;
-
Direct relatives of the above-mentioned natural persons, including spouses, parents, and adult children.
III. Stock Trading by Relevant Personnel and Institutions in the Transaction
Based on the "Inquiry Certificate of Shareholding and Share Change of Information Disclosure Obligors" and "Shareholder Share Change Detailed List" issued by China Securities Depository and Clearing Corporation Limited Shenzhen Branch, and the self-inspection reports, relevant explanations, and commitments provided by relevant insider information subjects, the stock trading of the listed company by the relevant parties within the inspection scope during the self-inspection period is as follows:
(I) Stock Trading by Natural Persons in Mindray Bio-Medical
During the self-inspection period, the stock trading of Mindray Bio-Medical by relevant natural persons is as follows: